Batu Biologics Awarded Exclusive License From University of California, San Diego (UCSD) for Drug That Stimulates Immune System To Kill Cancer

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immunotherapy company developing an anti-angiogenic cancer vaccine, announced today the signing of a license agreement with the Regents of the University of California, granting exclusive rights to novel peptide drugs developed at UC San Diego that have been proven to stimulate cancer-killing immune responses. Batu Biologics plans to utilize the licensed technology to enhance the potency of the antigen-specific immune response induced by the company’s novel ValloVax™ lung cancer vaccine. The company also plans to commercialize the UC San Diego technology as a standalone treatment for patients with melanoma.

Help employers find you! Check out all the jobs and post your resume.